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Aspirin may reduce the risk of cancer at some sites but its effect at the lung is unclear. We prospectively examined associations
between aspirin use and risk of lung cancer in 109348 women in the Nurses’ Health study from 1980 to 2004. During this time, 1360
lung cancers were documented in participants 36–82 years of age. Aspirin use and smoking were assessed every 2 years. Risk of lung
cancer was a non-significant 16% lower for regular aspirin users of one or two tablets per week and a significant 55% higher for users
of 15 or more tablets per week compared with women who never regularly used aspirin. Results were similar when limited to never
smokers. For both the low and high quantity aspirin users, risk of lung cancer did not decline or increase with longer durations of use,
and associations attenuated as the latency period between aspirin assessment and lung cancer diagnosis was lengthened. Our findings,
together with those from previous clinical trials and prospective studies, do not provide consistent evidence that aspirin influences the
development of lung cancer and further investigation is required with adjustment for smoking.
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Regular use of aspirin reduces the risk of colorectal adenoma and
cancer (Benamouzig et al, 2005), most likely through the inhibition
of cyclooxygenase enzymes, restoration of normal apoptosis, and
reduction of angiogenesis (Zha et al, 2004). However, the influence
of aspirin at other tumour sites is less clear. For lung cancer,
several meta-analyses with different coverage of published results
have offered varying results and interpretations. Of the two that
focused solely on lung cancer, aspirin users were found to have a
significant 27% lower risk in one (Khuder et al, 2005) and a non-
significant 9% lower risk in the other (Hernandez-Diaz and
Rodriguez, 2007). In two other meta-analyses in which lung cancer
was embedded in a wider review of many cancers, the first
reported a 16% lower risk for aspirin users that was compatible
with no effect or a slightly reduced risk (Gonzalez-Perez et al,
2003), and the other, limited to cohort studies, reported no
association (Bosetti et al, 2006). In general, these meta-analyses
concluded that a chemopreventive value of aspirin for lung cancer
should be interpreted with caution owing to the limitations of the
available studies and the heterogeneity of study designs and
results. The authors called for larger studies with better exposure
characterisation of dose–response measures and detailed adjust-
ment for smoking. In an attempt to resolve these uncertainties, we
examined relations between regular aspirin use and risk of invasive
lung cancer among women in the Nurses’ Health Study (NHS)
cohort, taking into consideration quantity, frequency, and dura-
tion of use and latency between exposure and diagnosis, while
controlling for detailed smoking characteristics. We placed our
results within a wider context by conducting a literature review
focused on clinical trials and prospective studies that, like our
study, had a quantitative measure of aspirin use and controlled for
smoking in analyses.
METHODS
Study population
The NHS was established in 1976 when 121700 female registered
nurses, 30–55 years of age, returned a mailed questionnaire. The
NHS was approved by the Institutional Review Board of the
Brigham and Women’s Hospital in Boston. Using mailed ques-
tionnaires, participants provided a disease history and information
about their personal characteristics and behaviours at baseline,
and every 2 years they have updated and extended these data and
reported newly diagnosed diseases on follow-up questionnaires.
Deaths are commonly reported by families or the postal service
and are confirmed through the National Death Index.
For this investigation, analysis began in 1980 when aspirin use
was first ascertained, and follow-up for incident lung cancer
continued until June 2004. The baseline study population consisted
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non-melanoma skin cancer) and provided information on their
smoking status and aspirin use. A total of 109348 women, 34–82
years of age over the follow-up period, contributed approximately
1.9 million person-years. The follow-up rate for this study
population was 95%.
Lung cancer cases
When lung cancer was reported by a cohort member or identified
from a death report, we sought medical records for confirmation
and date of diagnosis. Between 1980 and 2004, 1446 incident lung
cancers were reported among the women in this study population,
of which 1360 were confirmed as cases, with a median age at
diagnosis of 65 years (range 36–82 years). The majority of lung
cancers were adenocarcinomas (46%), small cell (17%), or
squamous cell (15%) tumours. The 86 unconfirmed lung cancers
were either metastatic from another site or lacked a follow-up
response from the participant and were censored at time of self-
report.
Aspirin assessment
Aspirin use was first assessed in 1980, when participants were
asked if they used aspirin in most weeks, and if so, to write the
number of years of use and the number of aspirin tablets
consumed per week. On subsequent biennial questionnaires,
participants were asked if they were a regular aspirin user over
the past 2 years and tablets per week and/or days per week of use
were assessed with categorical responses. In 2000 and 2002,
participants were additionally asked whether they took standard
dose (325mg or more) or low-dose (100mg or less) aspirin. We
converted reported tablets per week of low-dose aspirin into the
equivalent tablets of standard dose.
In this analysis, we reclassified participants in each 2-year
follow-up cycle by status and quantity (1–2, 3–5, 6–14, X15
tablets per week) of aspirin use. A participant was classified as a
current aspirin user if she reported at least 1 tablet per week or 1
day per week of regular use for the last 2 years; a past user if she
did not qualify as a current user but had been previously classified
as such; or a never user if she had never been classified as a current
user during cohort follow-up. Duration was calculated for current
users in each follow-up cycle as years of continuous aspirin use.
To determine reasons for aspirin use in this cohort, we had
queried a sample of 100 women who reported taking 1–6 tablets
per week in 1980, 1982, and 1984 (90% response) and 100 women
who reported taking 7 or more tablets per week in those years
(92% response). In both groups, the major reasons for aspirin use
were headache, arthritis, and/or musculoskeletal pain. Less than
10% of both the lower and higher quantity users cited
cardiovascular disease prevention.
Smoking and other covariates
On the initial NHS questionnaire, participants reported whether
they were a current smoker or had ever smoked in the past, the age
at which they began to smoke, the number of cigarettes typically
smoked in a day, and the age at which they stopped smoking. On
each subsequent biennial questionnaire, participants again re-
ported whether they currently smoked and their daily quantity of
cigarette use. In this analysis, we reclassified participants in each
2-year follow-up cycle by smoking status, cigarettes smoked per
day among current smokers, time since quitting among past
smokers, and age at start of smoking among ever smokers. Pack-
years were also calculated in each cycle as the product of years of
smoking and packs of cigarettes smoked per day.
Height was reported in 1976 and body mass index (BMI in
kgm
 2) was calculated with each biennial report of body weight.
Menopausal status and use of oestrogen replacement therapy were
updated every 2 years. The total number of hours per week of
physical activity was ascertained in 1980 and on eight subsequent
questionnaires. Diet was assessed with a food frequency ques-
tionnaire six times beginning in 1980 and daily intakes of fruits,
vegetables, a-carotene, lycopene, vitamin C, vitamin E, total fat,
and alcohol were calculated.
Statistical analysis
Participants contributed person-time from the return date of their
1980 questionnaire until a report of any other cancer except non-
melanoma skin cancer, death, or end of follow-up on 1 June 2004.
The median follow-up time per participant was 23.7 years. The
most recent data on aspirin use and all covariates were used to
allocate person-time to the appropriate category for each variable
at the beginning of every 2-year follow-up cycle. Participants did
not contribute person-time in any follow-up cycle in which they
were missing aspirin or smoking status.
Age-adjusted incidence rates of lung cancer were determined
within categories of aspirin use and relative risks (RRs) were
calculated as the ratio of the rate in each category of use compared
Table 1 Age-standardised characteristics
a of the study population of women by status and quantity of regular aspirin use over follow-up, 1980–2004
Aspirin use
Current tablets per week
Never Past Current 1–2 3–5 6–14 X15
Age, years (mean) 53 60 57 56 57 59 55
Never smoker (%) 44 44 44 46 44 42 42
Past smoker (%) 35 40 38 38 38 39 35
Current smoker (%) 21 15 18 17 18 19 22
Cigarettes per day
b (mean) 19 18 19 18 18 19 20
Years since quit smoking
c (mean) 17 18 17 18 17 17 16
Pack-years of smoking
d (mean) 25 22 24 23 23 25 27
BMI, kgm
 2 (mean) 25.3 26.2 25.8 25.6 25.6 26.3 26.6
Physical activity, hours per week (mean) 2.9 2.8 2.9 2.9 2.9 2.9 2.8
Post-menopausal (%) 69 69 69 68 69 70 70
oestrogen replacement therapy
e (%) 28 44 36 36 37 38 32
Abbreviation: BMI¼body mass index.
aCalculated over all person–years of follow-up and standardised to the age distribution of the study population.
bAmong current smokers.
cAmong past smokers.
dAmong past and current smokers.
eamong post-menopausal women.
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models to adjust simultaneously for age, smoking characteristics,
and the other potential confounders. To assess dose–response
effects for duration of aspirin use, P-values for linear trend were
calculated using medians per category.
Literature review
Relevant papers were sought electronically and by hand. The
PubMed database was searched without limits for ‘aspirin and lung
and cancer’. Reference lists of all articles of interest were scanned
for additional manuscripts and all papers citing two of the earliest
relevant publications (Peto et al, 1988; Thun et al, 1993) were
tracked through Science Citation Index. We reviewed all papers
with original data that assessed the relation between aspirin use
and lung cancer incidence or mortality. We excluded retrospective
analyses (Rosenberg 1995; Harris et al, 2002; Moysich et al, 2002;
Muscat et al, 2003) because of potential biases in aspirin recall and
selection of controls and the observed heterogeneity of results
from case-control and cohort studies in previous reviews. We also
excluded prospective studies that did not account for smoking
(Paganini-Hill et al, 1989; Friis et al, 2003; Sorensen et al, 2003) or
had no quantitative measure of aspirin use (Shreinemachers and
Everson, 1994; Ratnasinghe et al, 2004) because these factors likely
influence the association between aspirin and lung cancer. After
exclusions, we identified nine studies that met our criteria for
inclusion in the review (see Table 4). Confidence intervals (CIs)
were missing from one paper (Peto et al, 1988) for which we
calculated approximate intervals around the RR.
RESULTS
The characteristics of the women in the study population are
shown in Table 1 by status and quantity of regular aspirin use over
the 1980–2004 follow-up period. Current and past aspirin users
were older than those who never used aspirin on a regular basis (57
and 60 vs 53 years, respectively). After adjusting for age
differences, the percent of women who smoked varied little
between the never (21%) and current (18%) aspirin users, though
among the current users, the likelihood of smoking and daily
cigarette use increased with increasing aspirin tablets per week.
The highest quantity aspirin users had the highest BMI and the
post-menopausal women who never used aspirin regularly were
least likely to use oestrogen replacement therapy. No differences
by aspirin use were detected for the dietary variables nor for the
single assessment of exposure to second-hand smoke in 1982 (ie
number of adult years spent living with someone who smoked
regularly, and hours per week exposed to cigarette smoke from
people at home or work) (data not shown).
In the age-adjusted analysis, current aspirin users had a
modestly lower risk of lung cancer when compared with women
who never used aspirin regularly, and the RR was attenuated and
became null after the smoking factors were added to the model
(Table 2). However, when we examined the influence of aspirin
according to quantity consumed, we observed a non-significant
16% lower risk for current users of 1 or 2 tablets per week (low
quantity), a significant 55% increased risk for current users of 15
or more tablets per week (high quantity), and no risk or benefit for
women using between 3 and 14 tablets per week. Results were
essentially unchanged when all covariates were added to the model
or when pack-years were used to control for smoking instead of
age at start, years since quit, and cigarettes per day (data not
shown). Frequency of aspirin use exhibited an association with
lung cancer that was similar to that seen for quantity, with a lower
risk for use on 1 day per week (RR¼0.85, 95% CI 0.69–1.04) and
Table 3 Relative risks of lung cancer in women using 1 to 2 or 15 or more aspirin tablets per week by duration of use and by latency period between
aspirin assessment and lung cancer diagnosis
1–2 aspirin tablets per week X15 aspirin tablets per week
Duration of use
a P-Y
b Cases RR
c (95% CI
d) P-Y
b Cases RR
c (95% CI
d)
o2 years 202.5 119 0.86 (0.68–1.07) 27.0 33 1.68 (1.15–2.45)
2–5.9 years 153.8 81 0.87 (0.67–1.14) 21.1 20 1.44 (0.90–2.30)
X6 years 69.5 29 0.75 (0.50–1.19) 15.1 11 1.49 (0.81–2.76)
P for trend
e 0.66 0.31
Latency period
f P-Y
g Cases RR
c (95% CI
d) P-Y
g Cases RR
c (95% CI
d)
0t oo2 years
h 445.1 234 0.84 (0.70–1.02) 65.6 65 1.55 (1.17–2.06)
2t oo4 years 397.7 238 0.88 (0.73–1.05) 57.8 53 1.24 (0.92–1.68)
4t oo6 years 359.5 240 0.91 (0.76–1.09) 50.3 51 1.19 (0.88–1.62)
6t oo8 years 323.2 256 1.02 (0.86–1.22) 43.2 45 1.15 (0.84–1.59)
Abbreviations: P-Y¼person–years; RRs¼relative risks; CI¼confidence intervals.
aDuration was calculated as continuous years of aspirin use among current users.
bP-Y of
follow-up, in thousands, from 1980 to 2004.
cRRs adjusted for age, smoking status, age at start of smoking (past and current smokers), years since quit smoking (past smokers),
and cigarettes per day (current smokers).
d95% CI.
eP-value for linear trend over median values within categories of years of aspirin use.
fDuring the latency periods for users of
1–2 aspirin tablets per week, women were censored if they reported X15 tablets per week; during the latency periods for users of X15 aspirin tablets per week, women were
censored if they reported 1–2 tablets per week.
gP-Y of follow-up, in thousands, through 2004 and beginning in 1980 for a latency of 0 to o2 years; in 1982 for a latency of 2 to
o4 years; in 1984 for a latency of 4 to o6 years; and in 1986 for a latency of 6 to o8 years.
hA latency of o2 years is the same as current users in Table 2 because aspirin use
was assessed every 2 years.
Table 2 Relative risks of lung cancer in women by status
a and quantity of
aspirin use
Age-adjusted Smoking-adjusted
P-Y
b Cases RR
c (95% CI
d)R R
e (95% CI
d)
Never aspirin use 418.0 236 1.00 1.00
Past aspirin use 501.9 405 0.84 (0.71–0.99) 0.97 (0.82–1.15)
Current aspirin use 1016.0 719 0.91 (0.78–1.06) 1.00 (0.86–1.16)
1–2 tablets per week 445.1 234 0.73 (0.60–0.87) 0.84 (0.70–1.02)
3–5 tablets per week 201.8 134 0.86 (0.70–1.07) 0.98 (0.79–1.21)
6–14 tablets per week 239.7 233 1.04 (0.86–1.25) 1.06 (0.88–1.28)
X15 tablets per week 65.6 65 1.58 (1.19–2.09) 1.55 (1.17–2.06)
Abbreviations: P-Y¼person–years; RRs¼relative risks; CI¼confidence intervals.
aCurrent users reported a minimum of 1 tablet per week or 1 day per week of
regular aspirin use over the previous 2 years; past users qualified as a current user
sometime during cohort follow-up; never users never qualified as a current user.
bP-Y
of follow-up, in thousands, from 1980–2004.
cRRs adjusted for age.
d95% CI.
eRR
adjusted for age, smoking status, age at start of smoking, years since quit smoking
(past smokers), and cigarettes per day (current smokers).
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CI 1.00–1.40).
Associations between aspirin use and lung cancer did not differ
by smoking status. Even among the never smokers with 128 lung
cancers, the association was positive for high quantity users
(RR¼1.70, 95% CI 0.67–4.31) and inverse for low quantity aspirin
users (RR¼0.71, 95% CI 0.39–1.30). However, the inverse
association was only evident for adenocarcinoma tumours
(RR¼0.83, 95% CI 0.62–1.10) and in women less than 70 years
of age (RR¼0.77, 95% CI 0.62–0.95).
Duration of aspirin use was unrelated to lung cancer risk
(Table 3). With longer durations, risk neither notably decreased
for low quantity users nor increased for high quantity users. We
also examined timing of exposure to determine whether earlier use
was more relevant than current use for lung cancer aetiology.
However, for both low and high quantity users, the strongest
associations were those observed for current users (diagnosis
within the 2 years between aspirin assessments) and attenuated
with increasing latency between aspirin assessment and lung
cancer diagnosis.
The clinical trials and prospective studies of aspirin and lung
cancer that were included in our review are described in Table 4.
Despite the focus on research that included a quantitative measure
of aspirin use and accounted for smoking in analyses, results
remain inconsistent. The lowest RRs were reported from two
studies (Peto et al, 1988; Akhmedkhanov et al, 2002) that had few
lung cancer cases and very imprecise results. The only significant
inverse association was the 27% lower risk in women in the Cancer
Prevention Study II cohort who used aspirin 1–15 times per
month for at least 1 year (Thun et al, 1993). Five other studies
reported non-significant risk reductions. In the Women’s Health
Study clinical trial (Cook et al, 2005), a 22% lower risk of lung
cancer was reported for the treatment group receiving 100mg of
aspirin every other day for 10 years, an amount similar to the
325mg of aspirin once or twice a week in our NHS women. Fewer
studies observed an increased risk of lung cancer for aspirin users.
The only one with a significant result was a nested case-control
study using the UK Health Improvement Network database in
which a 53% increased risk of lung cancer was reported for men
and women who received prescriptions for 150mg or more per day
of aspirin for at least 1 year (Hernandez-Diaz and Rodriguez,
2007). This increased risk is similar to what we observed for high
quantity aspirin users in our cohort but the aspirin intake on
which it was based is much lower.
DISCUSSION
In this prospective study of women, we observed a 16% lower risk
of lung cancer among regular users of one or two standard dose
aspirin tablets per week and a 55% increased risk among those
using 15 or more tablets per week for the past 2 years. It is difficult
to interpret these diverse findings and to conclude whether one or
both may be real effects or whether they are due to chance or
residual confounding by smoking. The observed benefit from low
quantity aspirin use may have been biased if women with heart
disease were prescribed aspirin and also told to quit smoking.
However, our results were unchanged when we excluded women
who reported angina or a myocardial infarction. If aspirin is
indeed beneficial in preventing lung cancer, it is anticipated to
operate through anti-inflammatory pathways mediated by COX-2,
the inducible form of the cyclooxygenase enzymes (Coussens and
Werb, 2002). However, this requires higher doses of aspirin (Thun,
2000), as shown for colorectal cancer in several previous studies
(Thun et al, 1993, Collet et al, 1999), including one within this NHS
cohort (Chan et al, 2005). In this investigation, a lower risk of lung
cancer was only observed for a quantity of aspirin use that was too
low to affect COX-2. The lack of an increasing benefit with longer
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ydurations of aspirin use was also in contrast to the previous studies
of colorectal cancer. If low-dose aspirin is indeed beneficial, it may
act through pathways that do not involve inflammation and COX
inhibition (Hanif et al, 1996).
No biologic mechanism is evident for our observed increased
risk of lung cancer for women using 15 or more aspirin tablets per
week, and it is likely at least partially the result of residual
confounding, given the major impact of smoking on lung cancer
and the positive association between smoking and aspirin use in
this cohort. It is also possible that higher quantities of aspirin were
used just prior to diagnosis to treat preclinical symptoms, though
we did not find evidence to support this. Among the high quantity
aspirin users, 12% of both the lung cancer cases and the non-cases
had switched from no use or low quantity aspirin use in the
previous assessment. The small size of the high quantity aspirin
group prevented a more thorough examination of confounding by
indication.
The prospective design of our study minimised the recall bias
inherent in retrospective investigations, and the 24 years of
biennial data collection provided updated information for accurate
assessment of aspirin use, including status, quantity, frequency,
and duration of use, and latency between aspirin exposure and
lung cancer diagnosis. Self-reported aspirin use is prone to error,
but is more likely to be accurate among the educated health
professionals in this cohort. Moreover, such error would be
random and would only have attenuated our results towards the
null. The repeated biennial data collections also provided detailed
and updated assessment of smoking, the primary confounder in
lung cancer analyses. The importance of this confounding is
demonstrated by the attenuation of the RR from 0.73 to 0.84 for
women using 1–2 aspirin tablets per week when age at start of
smoking, current cigarettes per day, and time since quit were
added to the model. We acknowledge that measurement error
remains in our smoking assessment, and it is possible that a more
perfect assessment could further attenuate or nullify this associa-
tion. On the other hand, we observed a lower risk of lung cancer
for low quantity aspirin use even among the never smoking women
in this cohort.
Our findings, together with those from previous clinical trials
and prospective studies, do not offer consistent evidence that
aspirin use is independently associated with risk of lung cancer. If
there is indeed any effect of aspirin, future studies will require
careful assessment of quantity and frequency of aspirin use, along
with detailed histories of smoking and comorbidities.
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